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2Key Points:
We found no evidence of somatic NLRP3 mosaicism in the pathogenesis of SchnitzlerÕs
syndrome.
Pathogenic inflammasome activation is supported by: increased apoptosis-associated speck-
like protein with CARD domain, IL-18, IL-6 and anakinra response.
Abstract
To date, the pathogenic mechanisms underlying SchnitzlerÕs syndrome remain obscure, in
particular the interplay between the monoclonal protein and increased IL-1beta production,
although interest in the contribution of genetic factors has been fuelled by detection of
somatic NLRP3 mosaicism in two patients with the variant-type SchnitzlerÕs syndrome. At
two specialist UK centres we have identified 21 patients, who fulfilled diagnostic criteria for
SchnitzlerÕs syndrome with urticarial rash, fever, arthralgia and bone pain; 47% reported
weight loss, 40% fatigue and 21% lymphadenopathy. An IgM kappa paraprotein was detected
in 86%, the remainder had IgM lambda or IgG kappa. Patients underwent search for germline
and somatic mutations using the next generation sequencing (NGS) technology. Moreover,
we designed a panel consisting of 32 autoinflammatory genes to explore genetic
susceptibility factor(s) to SchnitzlerÕs syndrome. Genetic analysis revealed neither germline
nor somatic NLRP3, TNFRSF1A, NLRC4 or NOD2 mutations, apart from one patient with
germline NLRP3 p.V198M substitution. The pro-inflammatory cytokines and extracellular
apoptosis-associated speck-like protein with CARD domain (ASC) measured in the
SchnitzlerÕs syndrome patients serum during active disease were significantly higher than
healthy controls. 95% of our cohort achieved a complete response to recombinant IL-1
receptor antagonist (anakinra). Our findings do not support a role for somatic NLRP3
mosaicism in the disease pathogenesis; although elevated levels of ASC, IL-6 and IL-18 in
3patientsÕ serum, and the response to anakinra, suggest that SchnitzlerÕs syndrome is
associated with upregulated inflammasome activation. Despite its rarity SchnitzlerÕs
syndrome is an important diagnosis as treatment with IL-1 antagonists dramatically improves
patientsÕ quality of life.
Introduction
SchnitzlerÕs syndrome is a very rare, adult-onset, apparently acquired autoinflammatory
disease. It was first described in 1972 by the French dermatologist, Dr Liliane Schnitzler,
with just over 300 cases reported to date. A required hallmark of the disease is the presence
of a monoclonal protein, which is IgM-kappa in the vast majority of reported cases (classical
type), although monoclonal IgG has been identified in a minority (variant type).1 The clinical
phenotype varies to some extent between patients, but the presence of chronic urticarial-
looking rash and a monoclonal IgM or IgG paraprotein are the obligate Strasburg criteria for
diagnosis.2 Other less frequent symptoms, constituting minor diagnostic criteria include
recurrent fever, bone pain, lymphadenopathy, headache, myalgia, arthralgia, fatigue, weight
loss, peripheral neuropathy, neutrophilic dermal infiltrate on skin biopsy, leukocytosis and/or
elevated plasma C-reactive protein (CRP). Evolution of the, usually quite subtle and
asymptomatic, underlying clonal disorder to lymphoplasmacytic lymphoma (LPL),
Waldenstrm macroglobulinemia (WM), or IgM myeloma has been reported to occur in 15 to
20% of patients over median follow-up of 13 years from diagnosis,3 which appears broadly
comparable with that reported for IgM monoclonal gammopathy of unknown significance
(MGUS) (18% at 10 years).4
Clinically, with the exception of adult onset, SchnitzlerÕs syndrome bears a striking
resemblance to the cryopyrin-associated periodic syndrome (CAPS). This autosomal
dominant disorder is caused by gain-of-function mutations in the NLRP3 gene, which
4encodes a key component of the NLRP3-inflammasome and disease-associated mutations
result in marked upregulation of inflammasome activity and substantially increased
production of IL-1beta. CAPS is characterised by an urticaria-like rash from early infancy,
fever and inflammation involving many organ systems, and is associated with a significant
risk of development of AA amyloidosis.
A further similarity between SchnitzlerÕs syndrome and CAPS is their dramatic response to
IL-1 antagonists, implying a pivotal role of excess IL-1 production in their pathogenesis.5-7
No IL-1 blocking agents have yet been specifically licenced for the extremely rare indication
of SchnitzlerÕs syndrome. To date, anakinra (recombinant IL-1 receptor antagonist) has been
used most often for the treatment of patients with SchnitzlerÕs syndrome but canakinumab,
monoclonal antibodies against IL-1beta and rilonacept (an IL-1 -1 TRAP) have also been
reported to induce complete disease responses.8-10 Despite substantial clinical similarities
between CAPS and SchnitzlerÕs syndrome, the pathogenic mechanisms underlying the latter
syndrome remains obscure, in particular the interplay between the monoclonal protein and
increased IL-1beta production. Thus far no genetic influence has been identified in
SchnitzlerÕs syndrome, although speculation about the contribution of genetic factors has
been fuelled by the finding of the common NLRP3 p.V198M variant in two patients with the
classical type SchnitzlerÕs syndrome,11, 12 and the detection of somatic NLRP3 mosaicism in
two patients with the variant-type SchnitzlerÕs syndrome.13
We report here a study of the clinical features and response to treatment with IL-1 blockade
in 21 patients with SchnitzlerÕs syndrome identified at two specialist UK centres. The
recognition that adult-onset CAPS may be caused by somatic NLRP3 mutations and the close
clinical similarity to SchnitzlerÕs syndrome raises the possibility that somatic NLRP3
mosaicism could contribute to the disease pathogenicity, as de Koning et al previously
reported.13 To address this hypothesis, we used NGS technology to search for somatic NLRP3
5mutations in our cohort of patients. Moreover, we have looked for a common
susceptibility factor by targeting 32 genes associated with inherited autoinflammatory
diseases. We have measured the levels of pro-inflammatory cytokines and the extracellular
apoptosis-associated speck-like protein with CARD domain (ASC) aggregates during an
active disease state in the SchnitzlerÕs syndrome patientsÕ serum.
Patients and Methods
Between 2000 and 2015, 18 patients referred to the autoinflammatory disorders clinic at the
National Amyloidosis Centre (NAC) in London have been diagnosed with SchnitzlerÕs
syndrome according to the Strasbourg criteria. Three further patients were identified at the
specialist unit for autoinflammatory disorders at Leeds Teaching Hospitals NHS Trust.
All patients underwent comprehensive clinical and laboratory investigations including routine
blood and urine biochemistry, a search for a monoclonal protein by immunofixation,
electrophoresis of serum and urine, and serum free light chains, serial measurements of
inflammatory markers serum amyloid A protein (SAA) and C-reactive protein (CRP) and
skin and bone marrow biopsies.
Informed consent was provided by all subjects, and the ethical approval for the study was
obtained from Royal Free Hospital and University College Medical School Research Ethics
Committee for this retrospective study (REC reference number 06/Q0501/42) and from Leeds
(East) Research Ethics Committee (04/Q1206/107), and it was in accordance with the
Declaration of Helsinki.
Genetic studies
All genetic analyses were performed on DNA samples isolated from whole blood. The
NLRP3 gene, exons 3, 4 and 6, was initially analysed by Sanger sequencing using methods
6previously described.12 Subsequently, all samples underwent NGS analysis using ampliconÐ
based deep sequencing (ADS) and sequenced on either an IonTorrent or Illumina MiSeq
platforms. The mean depth of cover for each amplicon was 3500X, which was sufficient to
detect somatic mosaicism down to 3%. 14 Sorted bam files aligned to GRCh37 with BWA-
MEM were assessed using GATK DepthOfCoverage targeted at the genomic interval
1:247579200-247612650.
The Agilent EArray online tool (https://earray.chem.agilent.com/suredesign/) was used to
design an NGS gene panel which targets 32 genes associated with monogenic
autoinflammatory diseases (Supplementary materials) 15. Captured and indexed libraries
(QXT Target Enrichment System) were sequenced as a multiplex of 16 samples on an
Illumina MiSeq sequencer in paired-end mode. The mean depth of cover for each amplicon
was 250X, which was sufficient to detect somatic mosaicism down to 5%. 15
Read alignment, variant calling, and annotation were performed using Agilent Sure Call v3.0
software.
Pro-inflammatory cytokines and the extracellular ASC protein aggregates detection
Serum was separated from whole blood collected into tubes containing sodium polyanethol
sulfonate (SPS) and stored at -30oC. Our selection criteria for this study was samples
collected from patients before commencing therapy with IL-1 blocking agent. Seventeen
SchnitzlerÕs syndrome patients were included as well as seven CAPS patients who had
germline mutation in NLRP3 gene; in addition serum was obtained from healthy controls
(HC). In the remaining four SchnitzlerÕs syndrome patients pre-treatment serum was not
available.
Cytokine measurements
7The Meso Scale Discovery (MSD) platform was utilised to detect the following cytokines:
฀I฀L฀-฀1Į฀,฀ ฀I฀L฀-฀1ȕ฀,฀ ฀T฀N฀F฀-Į฀,฀ ฀I฀F฀N฀-Ȗ฀,  I L -฀6฀,฀ I฀L฀-฀8฀,  ฀I฀L฀-฀1฀0฀,฀ ฀I฀L฀-฀1฀β฀p฀4฀0฀,฀ ฀I฀L฀-฀1฀β฀p฀7฀0฀,฀ ฀a฀n฀d฀ ฀I฀L฀-฀1฀7Į฀.฀ ฀M฀D฀S฀ 
platform allows for the detection of 10 separate assays within a single well of a 96-well plate,
combining both electrochemiluminscence (ECL) and spatial gridding technology. Subsequent
detection of cytokines was achieved by the addition of an MSD ECL molecule (Sulfo-
Tag), which requires electrical stimulation for the activation of its chemiluminescence
properties. Imaging of the resulting light signal was measured using the MSD Sector Imager
instrument. The reference ranges are based on the upper and lower limits detected in the
serum of 20 healthy controls.
IL-18 levels were measured using ELISA: Human IL-18 Matched Antibody Kit (Catalogue
no. BMS267-2MST, Thermo Fisher Scientific, UK). 96 well plates were pre-coated with
human monoclonal IL-18 antibody and incubated overnight. Serum samples and standards
were added to the wells, followed by the addition of IL-18 antibodies labelled with biotin, in
combination with Streptavidin-HRP in order to form immune complexes. Unbound material
was washed away, with Chromogen solution added until the transformation of the colourless
solution to blue. The 96 well plate was then measured using the Multiskan microplate reader
(Thermo Fisher Scientific, UK) and results are expressed as pg/ml.
Detection of ASC protein aggregates (specks) in serum
200µl of healthy control (HC) or patient serum were incubated with 5µl of PE anti-ASC
(TMS-1) antibody (Cat. Number 653904, Biolegend, UK) for 1 hour, and subsequently
analysed on the LSRII flow cytometer instrument (BD Biosciences, UK). Non-fluorescent
1µm microspheres (Cat. Number F13838 Thermo-Fisher Scientific, UK) were used as a
guide to gate around ASC specks. ASC speck events were reported as total events in the set
gate divided by 200 (ASC speck/µl).
8Quality of life (QoL) assessments
The QualityMetric SF36v2¨ Health Survey is designed to measure functional health and
well-being from the patientÕs perspective. There are eight health domains (physical
functioning, role physical, bodily pain, general health, social function, role emotional, mental
health and vitality) which are scored individually out of 100 points, and the result expressed
in comparison to American norms. Scores closer to 100 represent a better QoL and a change
of 10 points or more in a domain is considered clinically significant. Patients were asked to
complete the surveys before starting treatment and on treatment.
Statistics
The Kruskal-Wallis one way ANOVA test was used to determine statistical significance for
cytokine and ASC speck measurements.
Results
Patients
Clinical and laboratory findings in our cohort are presented in table 1. The median age at
disease onset was 54.7 years (range 37-79). All patients were of British Caucasian ancestry
and two thirds were male. All patients fulfilled the Strasbourg diagnostic criteria for
SchnitzlerÕs syndrome; they presented with urticarial rash, constitutional upset, fever
accompanied by fatigue, arthralgia, myalgia and bone pain. Six patients presented with rash
and severe fatigue, which preceded other symptoms for up to two years, but eventually all
subjects suffered febrile episodes with rigours and night sweats. The rash typically covered
the trunk and limbs, sparing the face, palms and soles (Figure 1 A to C). Symptoms were
initially intermittent, lasting from one to five days, but over time the disease evolved with
both more frequent and severe episodes. Eventually all had almost daily symptoms with a
9profound effect on their quality of life (Figure 2B). Additional findings in our cohort include
significant weight loss (47%), fatigue (40%), and lymphadenopathy (21%). Two patients
complained of headaches during the febrile episodes and one suffered with hearing loss.
Median baseline CRP level in our cohort was 67.6 mg/l (range 18-257). Sixteen patients had
skin biopsies, which were reviewed by a single international expert, Dan Lipsker, and all
were consistent SchnitzlerÕs syndrome. A low level paraprotein was identified in each case:
18 patients had IgM kappa type, two had IgM lambda and one IgG kappa. The most feared
complications of SchnitzlerÕs syndrome include AA amyloidosis and evolution to a
lymphoplasmacytic malignancy. To date, over a median follow up of 64 (range 19 to 113)
months, clonal disease progression requiring chemotherapy has not occurred in any patient,
and doubling of the paraprotein concentration has occurred in only one case.
One patient was diagnosed with AA amyloidosis and died of complications of renal failure
before treatment with anakinra. The median time from onset of symptoms to initiation of
treatment with anakinra in the remaining 20 cases was 62 months (range 21-276); 95%
reported disappearance of all symptoms accompanied by normalisation of plasma CRP
concentration (< 10 mg/l) (Figure 2A). Responses have been maintained for a median
treatment duration of 60 months (range 15-115). No patients have discontinued treatment and
adverse events have been confined to minor infections, none requiring secondary care
intervention and none directly attributed to anakinra therapy. Responses were accompanied
by improvements in quality of life (Figure 2B).
Genetic studies
Sanger sequencing of the NLRP3 gene confirmed the heterozygous, germline p.V198M
variant in our previously reported patient.12 NGS analysis confirmed the p.V198M
substitution, no additional nucleotide alternations, including somatic NLRP3 variants, have
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been identified, despite applying a very sensitive method for detection of somatic mutations.
Analysis of the targeted 32 gene panel associated with inherited autoinflammatory diseases
showed no somatic mutations in the TNFRSF1A, NLRC4 or NOD2 genes (associated with
dominant autoinflammatory diseases characterised by rash) and did not identify any genetic
factor predisposing to SchnitzlerÕs syndrome. The various rare variants identified in our
cohort with the minor allele frequency <0.01 (allele frequency was obtained from 1000
genome project and Exome Aggregation Consortium (ExAC) public databases) are listed in
Table 1. Notably, some of these variants including: NLRP7 p.R156Q in patient 1, NOD2
p.R684W in patient 4, CARD14 p.S200N in patient 11, and a compound NOD2 p.M863V and
p.A1006fs in patient 14 have previously been reported on Infevers database
(https://fmf.igh.cnrs.fr/ISSAID/infevers/) but their significance is currently unknown.
Detection of ASC protein aggregates and proinflammatory cytokines the serum
Extracellular ASC protein aggregates and cytokines levels were measured in the serum
collected before administration of IL-1 blocking therapy in 17 SchnitzlerÕs syndrome
patients, seven CAPS patients who had germline mutation in NLRP3 gene and in HC. The
Kruskal-Wallis one way ANOVA test was used to derive significances between the non-
parametric data obtained.
Median levels of extracellular ASC specks per µl of serum (ASC spec/ µl) in SchnitzlerÕs
syndrome subjects, CAPS patients and HC were: 385/µl (range 100-897); 334/µl (range 102-
546) and 106/µl (range 23-157) respectively (Figure 3A). Median concentration of IL-18 in
these three groups were: 750 pg/ml (range 371-1852); 688 pg/ml (range 411-1141) and 119
pg/ml (range 23-278) respectively (Figure 3B) and IL-6 were: 4 pg/ml (range 1-97); 3.7
pg/ml (range 1.8-52.6) and 0.3 pg/ml (range 0.2-0.8) respectively (Figure 3C). The levels of
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ASC specks, IL-6 and IL-18 were similar between SchnitzlerÕs syndrome and CAPS patients,
and both groups had significantly higher levels compared to HC (Figure 3A to C).
Discussion
SchnitzlerÕs syndrome is an extremely rare clinical entity whose definition includes the
presence of a monoclonal gammopathy, usually but not exclusively of IgM isotype. Whilst
monoclonal gammopathy is regarded as central to the diagnosis of SchnitzlerÕs syndrome, the
nature of the association remains unclear. A recent study identified somatic NLRP3
mosaicism in two cases with variant type SchnitzlerÕs syndrome using NGS analysis on DNA
samples isolated from whole blood.13 The mutation in each case was subsequently found to
be restricted to cells of myeloid lineage. The authors postulated that a population of myeloid
cells with an acquired NLRP3 mutation produces abnormally high quantities of IL-1beta,
inducing chronic stimulation and clonal expansion of local B cells expressing IgM or, less
commonly, IgG, implying that the M-protein might be a by-product of inflammation rather
than a pathogenic trigger.13 Our results reported in this study do not support this hypothesis.
We performed a highly sensitive NGS analysis, able to detect very low levels of somatic
mosaicism, on DNA samples isolated from 21 SchnitzlerÕs syndrome patients, and have not
identified either germline or somatic NLRP3 mutations in any of our cases, other than the
presence of p.V198M in the NLRP3 gene, a common variant of uncertain significance, in one
case. Recently, Zhou et al. and Mensa-Vilaro et al. reported two unrelated adult patients with
late onset but otherwise typical CAPS caused by myeloid-restricted somatic NLRP3
mutations, with no monoclonal gammopathy. 14, 16 Similarly, at the NAC, we have identified
eight such patients with mosaic NLRP3 mutations.17 There are striking similarities between
the two reported SchnitzlerÕs syndrome cases and the patients with late onset CAPS caused
by somatic NLRP3 mutations, although neither IgM nor IgG paraprotein were found in the
latter group. The phenomenon of transient paraproteinaemia in the serum of patients with
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acute and chronic inflammatory illnesses is well recognised although relatively poorly
reported and not well understood.18, 19 None of our 42 patients presenting after the age of 40
years with genetically confirmed CAPS and long standing untreated IL-1-mediated
inflammation had a MGUS of any isotype at presentation nor on follow up. These data are
supported by a similar absence of paraprotein development in 54 adult patients presenting to
our centre with confirmed untreated TRAPS or FMF. Consistent with the phenomenon of
transient paraproteinaemia, the two reported variant-type SchnitzlerÕs syndrome patients with
somatic NLRP3 mosaicism had a very low concentrations of IgG paraproteinemia, which was
undetectable at follow up. The persistence of IgM paraproteins in SchnitzlerÕs syndrome and
occasional progression to WM or LPL suggests a very different pathogenesis. A pathogenic
role for the monoclonal protein is supported by a single case report of remission of
SchnitzlerÕs syndrome after chemotherapy with rituximab-cyclophosphamide-dexamethasone
induced a complete clonal response in a patient with WM.20 Thus, we suggest that the two
reported cases could reasonably be diagnosed with late onset CAPS due to somatic
mosaicism rather than variant-type SchnitzlerÕs syndrome. Consequently we urge to search
for mosaic NLRP3 mutations in patients thought to have SchnitzlerÕs syndrome who do not
completely fulfil the Strasbourg criteria, given the possibility that these patients may indeed
have late onset CAPS. Such a diagnosis may facilitate access to treatment since the anti-IL-1
agents anakinra, canakinumab and rilonacept are all licenced for CAPS.
Furthermore, our data do not support somatic mosaicism in NLRP3, TNFRSF1A, NLRC4 or
NOD2 genes underlying the pathogenesis of this intriguing disease. NGS analysis of 32 genes
associated with inherited autoinflammatory diseases failed to reveal any common
susceptibility factor for this disorder. A number of novel and/or previously reported variants
were found, but whether they are incidental or relevant to the pathogenesis of SchnitzlerÕs
syndrome needs to be further investigated.
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Although we did not find any evidence for somatic mosaicism in NLRP3 gene, we obtained
an indirect evidence that SchnitzlerÕs syndrome is associated with an upregulated
inflammasome activation and cytokine release. High levels of ASC aggregates have
previously been identified in the serum of untreated CAPS patients who had either germline
or somatic NLRP3 mutation.17, 21 ASC specs levels in these patients were directly linked to
their disease severity. During pyroptosis (programmed cell death mediated by caspase-1)
ASC specks are released by dying cells and can propagate inflammation in the neighbouring
cells by activating the NLRP3-inflammasome and caspase-1, leading to release of active IL-1
beta.21 We assessed levels of the circulating ASC protein aggregates in our cohort before
starting therapy with IL-1 blocking agent and detected significantly higher levels of ASC
aggregates in the sera from SchnitzlerÕs syndrome patients when compared to HC, but similar
to that in CAPS patients. Our results suggest both diseases are associated with inflammasome
activation, but this is a relatively novel assay, not yet offered routinely as a diagnostic test
and our use of it here is exploratory. We have a number of caveats including the absence of
data on long-term stability of the ASC specs aggregates in frozen stored human sera,
moreover formation of ASC specks has not been systematically studied in situations where
NLRP3 inflammasome activation might occur as a result of physiological processes, such as
following invasive bacterial infection. Consequently, we do not yet know if elevated ASC
speck aggregates is either specific or discriminatory for SchnitzlerÕs syndrome and related
autoinflammatory disorders.
Quantifying circulating IL-1 beta is not practical, it is virtually undetectable in human plasma
even in patients with active CAPS 22, but elevated levels of both IL-6 and IL-18 have been
observed in patients with rheumatoid arthritis,23, 24 SchnitzlerÕs syndrome20, 25, 26 and
autoinflammatory diseases27 and thus can be used as a sensitive marker of disease severity.
IL-18, similar to IL-1 beta, requires processing by caspase-1 for its biological activation,
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whereas the production IL-6 in under tight control of IL-1 beta. We found that both IL-6 and
IL-18 levels were elevated in the sera from SchnitzlerÕs syndrome patients compared to HC
and similar to that in CAPS patients.
Despite its rarity SchnitzlerÕs syndrome is an important diagnosis to consider as spontaneous
remission of symptoms is unlikely and the impact on patient life is profound. Treatment with
IL-1 blocking agents effectively ameliorate the symptoms related to the auto-inflammatory
component of SchnitzlerÕs syndrome and abolishes the biochemical inflammatory response,
thereby dramatically improving patientsÕ quality of life (Fig 2B). The treatment is well
tolerated and abrogates the risk of developing AA amyloidosis, which is a known
complication of any inflammatory disorder associated with sustained overproduction of
serum amyloid A protein. To date, AA amyloidosis has been reported in seven of the 292
patients with SchnitzlerÕs syndrome (2%). In our cohort one patient died of AA amyloidosis
before treatment with anakinra could be administered. As yet there is no evidence that
treatment with any specific blockade of IL-1 adversely affects the behavior of the associated
B cell clone. Indeed, there is a single report suggesting the opposite, the monoclonal protein
concentration having fallen in one SchnitzlerÕs syndrome patient following anakinra
therapy,28 and benefits of anakinra have also been reported in patients with smouldering
myeloma evidenced by reduction of the proliferative index.29
To date, clinically significant progression of the clonal B cell disorder has not occurred in any
of our patients, and only one has seen a doubling of their low level paraprotein; none have
required chemotherapy as yet. Follow up is currently too short to draw any firm conclusions
as to whether anakinra treatment might beneficially affect clonal proliferation.
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Table 1. Clinical and laboratory findings in SchnitzlerÕs syndrome cohort
* Testing was limited to ADS for NLRP3 gene; ND-not done, ADS- ampliconÐbased deep sequencing
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Figures Legend:
Figure 1. Characteristic urticarial rash in a patient diagnosed with SchnitzlerÕs
syndrome. A) Posterior and B) Anterior trunk, C) Close up view of the skin lesions
Figure 2. Acute phase protein levels and Quality of life by SF36 before and during
treatment with anakinra. A) Acute phase protein CRP levels measured before administration
of treatment (median baseline 67 mg/l (range18-257)) and while on treatment (median baseline
5 mg/l (range 3-10)) showed a significant reduction p = <0.0001. B) Patients were surveyed
before starting anakinra, and whilst on treatment for 3 Ð 4 months. A comparison of the mean
scores in each domain before and on-treatment was statistically significant (Mann Whitney
p=0.0003) and clinically meaningful improvement, to well above that of healthy age matched
USA controls (normalised to 50), were seen in all domains (a change of 10 points or more is
considered clinically significant). PF=physical function, RP=role physical, BP=bodily pain,
GH=general health, VT=vitality, SF=social function, RE=role emotional, MH=mental health.
Figure 3. ASC protein aggregates and pro-inflammatory cytokines measured in the
serum obtained from two control groups and the SchnitzlerÕs syndrome patients prior
to their treatment with anakinra. A) Extracellular ASC specks per µl in the serum from
healthy controls (HC) (n=11), patients with SchnitzlerÕs syndrome (n=17) and CAPS (n=7).
Significant difference was observed between HC and SchnitzlerÕs syndrome (**p = 0.0151)
and between HC and CAPS (*p = 0.0304). B) IL-18 levels in HC (n=21), patients with
SchnitzlerÕs syndrome (n=17) and CAPS (n=7). Significant difference was observed between
HC and SchnitzlerÕs syndrome (****p = <0.0001) and between HC and CAPS patients (***p
= 0.0003). C) IL-6 levels in HC (n=12), patients with SchnitzlerÕs syndrome (n=17) and
CAPS (n=7). Significant difference was observed between HC and SchnitzlerÕs syndrome
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(***p= 0.0005) and between HC and CAPS (**p = 0.0016) patients. No significant
difference of ASC protein aggregates, IL-18 and IL-6 was observed between the SchnitzlerÕs
syndrome and CAPS cohorts. The Kruskal-Wallis one way ANOVA test was used to derive
significances between the non-parametric data obtained. P values of equal to or <0.05 were
regarded as significant.
Figure 1
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